Maruko Ichiro
Department of Ophthalmology, Fukushima Medical University School of Medicine of Medicine, 1 Hikarigaoka, Fukushima-shi 960-1295, Japan.
Nippon Ganka Gakkai Zasshi. 2012 Nov;116(11):1062-79.
Studies using indocyanine green angiography (ICGA) revealed that the main cause of central serous chorioretionopathy (CSC) stems from choroidal abnormalities such as choroidal vascular hyperpermeability. However, there are no methods to evaluate the choroid except for either the invasive ICGA or low-resolution ultrasonography. The recently developed enhanced depth imaging optical coherence tomography (EDI-OCT) technique can visualize the choroid appropriately and noninvasively using conventional OCT. EDI-OCT showed that both the affected and unaffected eyes in CSC patients have a thickened choroid; whereas the remarkably thickened choroid in Vogt-Koyanagi-Harada disease decreases immediately after corticosteroid treatment and the eyes with high myopia show a thinner choroid. We evaluated the choroidal thickness after treatment of CSC. The subfoveal choroidal thickness in typical CSC treated with laser photocoagulation showed no changes during the follow-up. On the other hand, the subfoveal choroid in chronic CSC treated with half-dose verteporfin photodynamic therapy (PDT) showed temporary thickening after 2 days but thinned back 1 month after treatment. Both the choroidal thickness and choroidal vascular hyperpermeability in ICGA decreased after PDT, but they did not change after laser photocoagulation. These findings suggest that PDT can affect the abnormal choroid directly and works through a different mechanism from conventional laser photocoagulation. It is important to evaluate the choroid using OCT in CSC and other macular diseases.
使用吲哚菁绿血管造影(ICGA)的研究表明,中心性浆液性脉络膜视网膜病变(CSC)的主要病因源于脉络膜异常,如脉络膜血管高通透性。然而,除了侵入性的ICGA或低分辨率超声检查外,没有其他方法来评估脉络膜。最近开发的增强深度成像光学相干断层扫描(EDI-OCT)技术可以使用传统的OCT适当地、非侵入性地可视化脉络膜。EDI-OCT显示,CSC患者的患眼和未患眼的脉络膜均增厚;而Vogt-小柳-原田病中明显增厚的脉络膜在皮质类固醇治疗后立即变薄,高度近视患者的眼睛脉络膜较薄。我们评估了CSC治疗后的脉络膜厚度。接受激光光凝治疗的典型CSC患者的黄斑中心凹下脉络膜厚度在随访期间无变化。另一方面,接受半剂量维替泊芬光动力疗法(PDT)治疗的慢性CSC患者的黄斑中心凹下脉络膜在治疗后2天出现暂时增厚,但在治疗后1个月又变薄。PDT后ICGA中的脉络膜厚度和脉络膜血管高通透性均降低,但激光光凝后无变化。这些发现表明,PDT可以直接影响异常脉络膜,其作用机制与传统激光光凝不同。在CSC和其他黄斑疾病中,使用OCT评估脉络膜很重要。